Article Simons e.a.: Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review. Critical Reviews in Oncology/Hematology, 153, p.103035. https://doi.org/10.1016/j.critrevonc.2020.103035
Article Frederix e.a.: Micro-costing Diagnostics in Oncology: From Single-Gene Testing to WholeGenome Sequencing. http://dx.doi.org/10.1101/19009969
Article Giesbertz e.a. : a duty to recontact in genetics: context matters https://www.nature.com/articles/s41576-019-0121-7
Article Mitchell e.a.: Experts reflecting on the duty to recontact patients and research participants; why professionals should take the lead in developing guideline. https://www.sciencedirect.com/science/article/pii/S1769721219300035?via%3Dihub (Corrected proofs)
Article Ploem e.a.: A duty to recontact in the context of genetics: futuristic or realistic? https://research.utwente.nl/en/publications/a-duty-to-recontact-in-the-context-of-genetics-futuristic-or-real
Article van de Ven e.a.: Variation in the time to treatment for stage III and IV Non-Small Cell Lung Cancer patients for hospitals in the Netherlands https://doi.org/10.1016/j.lungcan.2019.05.023
Article PATH Eijkelenboom e.a. : Recommendations for clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics https://link.springer.com/article/10.1007%2Fs00428-019-02555-3
Personalized medicine driven treatments in major diseases like advanced melanoma and non-small cell lung cancer (NSCLC) offer important health benefits to genetic subgroups, but can be expensive and may induce severe side effects. Whole Genome Sequencing (WGS) simultaneously tests for all relevant genetic aberrations in tumor tissue from individual cancer patients thereby allowing immediate selection of optimal therapy. This approach is likely to improve patient survival, avoid adverse effects, and to assist in controlling health care costs by offering treatment to only those identified to benefit.
The project team consists of a large nation-wide consortium embedded in the Center for Personalized Cancer Treatment (CPCT)/Hartwig Medical Foundation (HMF), covering all relevant disciplines (geneticists, pathologists, bio-informatics, cancer biologists, oncologists, health economists and ethical/legal experts). This approach will provide evidence for decision making on genetic testing for optimizing health and economic outcomes for current and future personalized cancer care.
Click 'read more' below for extensive information about the project.Read more
During the project duration 2016-2021 this Zenodo community is curated by the Data Steward of the project. Only project members and affiliated are able to publish outputs to this community.